Published in J Clin Endocrinol Metab on November 01, 2003
Alterations in the dynamics of circulating ghrelin, adiponectin, and leptin in human obesity. Proc Natl Acad Sci U S A (2004) 1.61
Ghrelin. Mol Metab (2015) 1.29
Comparison of glucostatic parameters after hypocaloric diet or bariatric surgery and equivalent weight loss. Obesity (Silver Spring) (2011) 1.14
Clinical review: The human experience with ghrelin administration. J Clin Endocrinol Metab (2013) 0.93
Integrating GHS into the Ghrelin System. Int J Pept (2010) 0.88
The decreased growth hormone response to growth hormone releasing hormone in obesity is associated to cardiometabolic risk factors. Mediators Inflamm (2010) 0.82
Reduction in hypophyseal growth hormone and prolactin expression due to deficiency in ghrelin receptor signaling is associated with Pit-1 suppression: relevance to the immune system. Brain Behav Immun (2008) 0.81
Effects of ghrelin on protein expression of antioxidative enzymes and iNOS in the rat liver. Arch Med Sci (2014) 0.79
Cortisol secretory parameters in young exercisers in relation to LH secretion and bone parameters. Clin Endocrinol (Oxf) (2013) 0.78
Bariatric surgery and T2DM improvement mechanisms: a mathematical model. Theor Biol Med Model (2012) 0.78
Metabolic responses to exogenous ghrelin in obesity and early after Roux-en-Y gastric bypass in humans. Diabetes Obes Metab (2017) 0.75
The endocrinology of aging. Science (1997) 3.28
Pituitary insufficiency. Lancet (1998) 2.93
Octreotide. N Engl J Med (1996) 2.67
A consensus on criteria for cure of acromegaly. J Clin Endocrinol Metab (2010) 2.33
Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N Engl J Med (2000) 2.16
Lithium deintercalation in LiFePO4 nanoparticles via a domino-cascade model. Nat Mater (2008) 2.15
Ghrelin, a natural GH secretagogue produced by the stomach, induces hyperglycemia and reduces insulin secretion in humans. J Clin Endocrinol Metab (2001) 2.13
Impairment of GH secretion in adults with primary empty sella. J Endocrinol Invest (2002) 2.09
Growth hormone secretagogue binding sites in peripheral human tissues. J Clin Endocrinol Metab (2000) 1.83
Exacerbation of motor tic and induction of new tic by haloperidol use. West J Med (1992) 1.78
Low dose (1 microg) ACTH test in the evaluation of adrenal dysfunction in pre-clinical Addison's disease. Clin Endocrinol (Oxf) (2000) 1.60
Consensus statement: medical management of acromegaly. Eur J Endocrinol (2005) 1.54
First-line therapy of acromegaly: a statement of the A.L.I.C.E. (Acromegaly primary medical treatment Learning and Improvement with Continuous Medical Education) Study Group. J Endocrinol Invest (2006) 1.52
Clinical-pathological changes in differentiated thyroid cancer (DTC) over time (1997-2010): data from the University Hospital "Maggiore della Carità" in Novara. Endocrine (2012) 1.50
"Nephritic flares" are predictors of bad long-term renal outcome in lupus nephritis. Kidney Int (1996) 1.49
Cardiovascular risk and metabolic syndrome in primary hyperparathyroidism and their correlation to different clinical forms. Endocrine (2013) 1.48
Activity of GH/IGF-I axis in patients with dilated cardiomyopathy. Clin Endocrinol (Oxf) (1999) 1.48
[Cushing's syndrome. II. New forms of treatment]. Ned Tijdschr Geneeskd (2006) 1.47
Free and total insulin-like growth factor I (IGF-I), IGF-binding protein-1 (IGFBP-1), and IGFBP-3 and their relationships to the presence of diabetic retinopathy and glomerular hyperfiltration in insulin-dependent diabetes mellitus. J Clin Endocrinol Metab (1997) 1.45
Circulating ghrelin levels in the newborn are positively associated with gestational age. Clin Endocrinol (Oxf) (2004) 1.44
Preliminary evidence that Ghrelin, the natural GH secretagogue (GHS)-receptor ligand, strongly stimulates GH secretion in humans. J Endocrinol Invest (2000) 1.44
Hypopituitaric patients with corticotropin insufficiency show marked impairment of the cortisol response to ACTH (1-24) independently of the duration of the disease. J Endocrinol Invest (2003) 1.43
Glucagon stimulates GH secretion after intramuscular but not intravenous administration. Evidence against the assumption that glucagon per se has a GH-releasing activity. J Endocrinol Invest (1994) 1.42
Postoperative metyrapone test in the early assessment of outcome of pituitary surgery for Cushing's disease. Clin Endocrinol (Oxf) (1997) 1.41
Non-acylated ghrelin counteracts the metabolic but not the neuroendocrine response to acylated ghrelin in humans. J Clin Endocrinol Metab (2004) 1.40
Activity of GH/IGF-I axis in trauma and septic patients during artificial nutrition: different behavior patterns? J Endocrinol Invest (2002) 1.40
ACROSTUDY: the Italian experience. Endocrine (2014) 1.38
Identification, characterization, and biological activity of specific receptors for natural (ghrelin) and synthetic growth hormone secretagogues and analogs in human breast carcinomas and cell lines. J Clin Endocrinol Metab (2001) 1.37
Endocrine activities of ghrelin, a natural growth hormone secretagogue (GHS), in humans: comparison and interactions with hexarelin, a nonnatural peptidyl GHS, and GH-releasing hormone. J Clin Endocrinol Metab (2001) 1.32
Somatostatin receptors in gastroentero-pancreatic neuroendocrine tumours. Endocr Relat Cancer (2003) 1.32
Transition process of patients with type 1 diabetes (T1DM) from paediatric to the adult health care service: a hospital-based approach. Clin Endocrinol (Oxf) (2008) 1.30
Pasireotide versus octreotide in acromegaly: a head-to-head superiority study. J Clin Endocrinol Metab (2014) 1.29
Administration of acylated ghrelin reduces insulin sensitivity, whereas the combination of acylated plus unacylated ghrelin strongly improves insulin sensitivity. J Clin Endocrinol Metab (2004) 1.28
Neurological dysfunction associated with nonketotic hyperglycemia. Arch Neurol (1968) 1.26
Thyroid incidentaloma identified by ¹⁸F-fluorodeoxyglucose positron emission tomography with CT (FDG-PET/CT): clinical and pathological relevance. Clin Endocrinol (Oxf) (2011) 1.25
Ghrelin-induced growth hormone secretion in humans. Eur J Endocrinol (2000) 1.24
Primary empty sella: Why and when to investigate hypothalamic-pituitary function. J Endocrinol Invest (2010) 1.21
Cerebral oedema complicating treated non-ketotic hyperglycaemia. Lancet (1969) 1.21
Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly. Lancet (2005) 1.18
Ghrelin and unacylated ghrelin stimulate human osteoblast growth via mitogen-activated protein kinase (MAPK)/phosphoinositide 3-kinase (PI3K) pathways in the absence of GHS-R1a. J Endocrinol (2006) 1.18
Chronic inflammation in psoriasis and obesity: implications for therapy. Med Hypotheses (2006) 1.16
Insulin-like growth factor binding protein-3 induces angiogenesis through IGF-I- and SphK1-dependent mechanisms. J Thromb Haemost (2007) 1.16
Sleep abnormalities in type 2 diabetes may be associated with glycemic control. Acta Diabetol (2008) 1.16
Relationships between IGF-I and age, gender, body mass, fat distribution, metabolic and hormonal variables in obese patients. Int J Obes Relat Metab Disord (1999) 1.11
Current management practices for acromegaly: an international survey. Pituitary (2011) 1.10
Clinical and prognostic value of serial renal biopsies in lupus nephritis. Am J Kidney Dis (1999) 1.07
Ghrelin and glucose homeostasis. Peptides (2011) 1.05
Quality of life in acromegalic patients during long-term somatostatin analog treatment with and without pegvisomant. J Clin Endocrinol Metab (2008) 1.05
Free-living amoebae, a training field for macrophage resistance of mycobacteria. Clin Microbiol Infect (2009) 1.05
C-peptide and the risk for incident complications and mortality in type 2 diabetic patients: a retrospective cohort study after a 14-year follow-up. Eur J Endocrinol (2012) 1.04
Ghrelin: more than a natural GH secretagogue and/or an orexigenic factor. Clin Endocrinol (Oxf) (2005) 1.04
Cancer mortality reduction and metformin: a retrospective cohort study in type 2 diabetic patients. Diabetes Obes Metab (2011) 1.04
Circulating cytokine balance and activation markers of leucocytes in Q fever. Clin Exp Immunol (1999) 1.03
Superior sagittal sinus thrombosis and pulmonary embolism: a syndrome rediscovered. Acta Neurol Scand (1992) 1.01
Activation of epileptogenic foci by hyperosmolality. Neurology (1967) 1.00
Normal age-dependent values of serum insulin growth factor-I: results from a healthy Italian population. J Endocrinol Invest (2008) 0.99
Cerebrospinal fluid leakage during transsphenoidal surgery: postoperative external lumbar drainage reduces the risk for meningitis. Pituitary (2004) 0.98
Oral glucose load inhibits circulating ghrelin levels to the same extent in normal and obese children. Clin Endocrinol (Oxf) (2006) 0.98
Combined treatment for acromegaly with long-acting somatostatin analogs and pegvisomant: long-term safety for up to 4.5 years (median 2.2 years) of follow-up in 86 patients. Eur J Endocrinol (2009) 0.98
Long-term follow-up of 'cured' prolactinoma patients after successful adenomectomy. Clin Endocrinol (Oxf) (1990) 0.97
Stimulatory effect of adrenocorticotropin on cortisol, aldosterone, and dehydroepiandrosterone secretion in normal humans: dose-response study. J Clin Endocrinol Metab (2000) 0.97
Retesting young adults with childhood-onset growth hormone (GH) deficiency with GH-releasing-hormone-plus-arginine test. J Clin Endocrinol Metab (2000) 0.96
Predictors of morbidity and mortality in acromegaly: an Italian survey. Eur J Endocrinol (2012) 0.96
Neuroendocrine tumors and somatostatin: imaging techniques. J Endocrinol Invest (2005) 0.96
Comparison between insulin-induced hypoglycemia and growth hormone (GH)-releasing hormone + arginine as provocative tests for the diagnosis of GH deficiency in adults. J Clin Endocrinol Metab (1998) 0.95
Ghrelin elicits a marked stimulatory effect on GH secretion in freely-moving rats. Eur J Endocrinol (2000) 0.94
Effects of short-term administration of low-dose rhGH on IGF-I levels in obesity and Cushing's syndrome: indirect evaluation of sensitivity to GH. Eur J Endocrinol (2001) 0.94
Arginine-induced hypophosphatemia and hyperkaliemia in man. Diabete Metab (1979) 0.94
The inhibitory effect of alprazolam, a benzodiazepine, overrides the stimulatory effect of metyrapone-induced lack of negative cortisol feedback on corticotroph secretion in humans. J Clin Endocrinol Metab (1999) 0.94
Cost-of-illness study in acromegalic patients in Italy. J Endocrinol Invest (2004) 0.94
Natural (ghrelin) and synthetic (hexarelin) GH secretagogues stimulate H9c2 cardiomyocyte cell proliferation. J Endocrinol (2002) 0.93
Cortistatin, but not somatostatin, binds to growth hormone secretagogue (GHS) receptors of human pituitary gland. J Endocrinol Invest (2001) 0.93
Ghrelin and its unacylated isoform stimulate the growth of adrenocortical tumor cells via an anti-apoptotic pathway. Am J Physiol Endocrinol Metab (2007) 0.93